Department of Geriatrics, First Hospital of Lanzhou University, Lanzhou, China.
Department of Gastroenterology and Oncology, Gansu Provincial Cancer Hospital, Lanzhou, China.
Front Endocrinol (Lausanne). 2023 Sep 25;14:1263861. doi: 10.3389/fendo.2023.1263861. eCollection 2023.
Although subclinical hypothyroidism (SCH) is related to abnormalities in left ventricular diastolic function, the use of levothyroxine as a regular treatment remains debatable. This meta-analysis aimed to determine whether thyroid hormone replacement therapy affects cardiac diastolic function in patients with SCH as measured by echocardiography.
This meta-analysis included a search of the EMBASE, PubMed, Web of Science, and Cochrane Library databases from their inception to May 18, 2023, for studies analyzing cardiac morphology and functional changes in patients with SCH before and after thyroid hormone replacement. The outcome measures were cardiac morphology and diastolic and overall cardiac function, as assessed using ultrasound parameters (including ventricular wall thickness, chamber size, mitral wave flow, tissue Doppler, and speckle tracking). The quality of the studies was assessed using the Newcastle-Ottawa Scale. The standard mean differences (MDs) and 95% confidence intervals (CI) were calculated using fixed- or random-effects models.
Seventeen studies met the inclusion criteria. A total of 568 patients participated and completed the follow-up. All studies specifically stated that serum thyrotropin levels returned to normal by the end of the study period. Compared with baseline levels, no significant morphological changes were observed in the heart. In terms of diastolic function, we discovered that the ratios of E-velocity to A-velocity (E/A) had greatly improved after thyroid hormone replacement therapy, whereas the ratios of the mitral inflow E wave to the tissue Doppler e' wave (E/e') had not. Global longitudinal strain (GLS) increased significantly after treatment with levothyroxine.
In adult patients with SCH, thyroid hormone supplementation can partially but not completely improve parameters of diastolic function during the observation period. This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 statement, an updated guideline for reporting systematic reviews (11) and was registered with INPLASY (INPLASY202320083).
尽管亚临床甲状腺功能减退症(SCH)与左心室舒张功能异常有关,但使用左甲状腺素进行常规治疗仍存在争议。本荟萃分析旨在确定甲状腺激素替代治疗是否会影响 SCH 患者的心脏舒张功能,方法是通过超声心动图测量。
本荟萃分析纳入了从成立到 2023 年 5 月 18 日在 EMBASE、PubMed、Web of Science 和 Cochrane Library 数据库中搜索分析 SCH 患者甲状腺激素替代前后心脏形态和功能变化的研究。结局指标为心脏形态和舒张及整体心功能,通过超声心动图参数(包括室壁厚度、心室大小、二尖瓣血流、组织多普勒和斑点追踪)评估。使用纽卡斯尔-渥太华量表评估研究质量。使用固定或随机效应模型计算标准均数差(MD)和 95%置信区间(CI)。
17 项研究符合纳入标准。共有 568 名患者参与并完成了随访。所有研究均明确表示,研究结束时血清促甲状腺激素水平恢复正常。与基线水平相比,心脏形态无明显变化。在舒张功能方面,我们发现甲状腺激素替代治疗后 E 速度与 A 速度的比值(E/A)显著改善,而二尖瓣血流 E 波与组织多普勒 e'波的比值(E/e')则没有。左甲状腺素治疗后整体纵向应变(GLS)显著增加。
在 SCH 成年患者中,甲状腺激素补充可部分改善,但不能完全改善观察期间舒张功能的参数。本荟萃分析根据系统评价和荟萃分析 2020 声明(11)和 INPLASY(INPLASY202320083)的更新指南进行。